TG THERAPEUTICS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $616.3 | $329.0 | $233.7 | $2.8 | $6.7 |
| Operating income | $123.3 | $41.9 | $20.6 | -$218.3 | -$344.8 |
| Net income | $447.2 | $23.4 | $12.7 | -$223.8 | -$348.1 |
| Balance Sheet | |||||
| Total debt | — | — | $105.2 | $76.7 | — |
| Cash Flow Statement | |||||
| Free cash flow | -$25.0 | -$40.6 | -$31.4 | -$176.2 | -$296.0 |
| Share repurchases | $91.2 | $8.8 | $0.0 | $0.0 | — |
Shares outstanding 153.1M · Free float 78.9%
Annual filing data through FY ended December 31, 2025; float as of October 9, 2026.